APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma  MT-601 demonstrated 66% objective response rate with 50% complete response in relapsed Non-Hodgkin lymphoma (NHL) patients in the ongoing APOLLO study First patient treated in Off-the-Shelf program (RAPID study) investigating MAR-T cells in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) cGMP manufacturing collaboration established with Cellipont Bioservices HOUSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based therapies, today reported corporate updates and financial results for the third quarter ended September 30, 2025. “Marker entered the second half of 2025 with strong...

MISSISSAUGA, Ontario, Nov. 14, 2025 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased to report its financial results for the third quarter ended September 30, 2025. “Last week, we announced a transformative financing following the successful commissioning of our electrolyzer at the largest onsite hydrogen fueling station in Ontario. We view this as a testament to our proprietary electrolyzer technology for cost-effective clean hydrogen production,” said Raveel Afzaal, President & CEO of Next Hydrogen. “This financing, once closed, is expected to fully fund us to cashflow positive while enabling us to scale our existing product line and launch our larger product line. We will execute on a capital light strategy...

–-Commercially Launched ORLYNVAH™ in the United States in August 2025– –Extended Cash Runway into Q2 2026– –Company to host conference call today at 8:30amET– DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. “We are thrilled to have launched ORLYNVAH™ in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs),” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. “The significance of this milestone cannot...

HALIFAX, Nova Scotia, Nov. 14, 2025 (GLOBE NEWSWIRE) — NexLiving Communities Inc. (“NexLiving” or the “Company”) announced operating and financial results for the three-month and nine-month periods ended September 30, 2025. Stavro Stathonikos, President & CEO commented: “2025 has so far been a year of strong execution producing a milestone quarter for NexLiving. Q3 FFO per share was the highest ever, having increased +30% year-over-year, driven by both operational improvements and acquisition growth. In late Q2 we brought management of our Saint John portfolio in-house, resulting in a +13% increase in same-property NOI. Our recent Winnipeg acquisition is already contributing to FFO, and as construction progresses on our five-phase Ottawa townhome project, we expect to exercise our cashless option and add high-quality assets...

– Completes IPO, Expands Patent Portfolio, and Strengthens Board Independence – TUCSON, Ariz., Nov. 14, 2025 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced financial results for the three and nine months ended September 30, 2025. Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc., commented, “The third quarter marked a pivotal moment for the company with the successful completion of its initial public offering in September. The IPO strengthened the balance sheet by retiring convertible debt, providing new capital to accelerate research, development, and commercial expansion across SynCardia’s life-saving artificial...

CALGARY, Alberta, Nov. 14, 2025 (GLOBE NEWSWIRE) — Atlas Energy Corp. (“Atlas” or the “Company”) (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce its unaudited consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the quarter ended September 30, 2025, are available on the Company’s SEDAR+ profile at www.sedarplus.ca. “The recent moderation in global oil prices and emerging forecasts for a potential oversupply in 2026 have added to an already constructive environment for disciplined capital deployment. These market dynamics have contributed to a meaningful expansion of Atlas’s deal pipeline over the last few months and strengthened the visibility of near-term actionable opportunities”, said Mark Hodgson, Atlas Energy’s President and Chief Executive Officer. “Within...

Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc. Agreement provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 million Closing is expected to occur by the end of January 2026CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter ended September 30, 2025. Acquisition by Day One Biopharmaceuticals, Inc. Yesterday, Mersana announced that it has entered into a definitive...

Earnings Call Scheduled for Friday, November 14, 2025, at 8:30 AM ET $20 Million in New Financing Completed Subsequent to Quarter-End De-SPAC Liabilities Reduced by Over 80% Since Fiscal 2024 Stockholders’ Equity Positive at $6.9 Million Third Correspondent Clearing Customer Signed and OnboardingTAMPA, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear Holdings” or the “Company”) today announced its financial results for the fiscal first quarter ended September 30, 2025, and provided a corporate update. The Company will host its earnings conference call this morning at 8:30 AM Eastern Time. “This quarter marks a key inflection point for AtlasClear,” said John Schaible, Executive Chairman of AtlasClear Holdings. “We have achieved positive stockholders’ equity, continued to streamline...

Substantially Exceeds Analyst Estimates, Achieves 115% Revenue Growth HAUPPAUGE, N.Y., Nov. 14, 2025 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (NASDAQ: AMPG), a leading designer, developer, and manufacturer of state-of-the-art signal processing components, low-noise amplifiers (LNAs), and advanced 5G/6G ORAN systems, today announced financial results for the third quarter ended September 30, 2025, marking another milestone toward profitability and continued operational momentum. Q3 2025 Financial HighlightsQuarterly revenue of $6.09 million, a 115% increase compared to $2.83 million in Q3 2024. Gross profit more than doubled to $2.96 million, representing a 48.6% gross margin, up from 47.5% in the prior-year period, up about 40% from Q2 2025 gross margins. Net loss significantly narrowed to $188,000 or $0.01 per share, compared...